Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 3Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Lymphoma, B-Cell 2Leukemia, Hairy Cell 2Leukemia 2Hodgkin Disease 2Carcinoma in Situ 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Prostatic Neoplasms 1Philadelphia Chromosome 1Papillomavirus Infections 1Oropharyngeal Neoplasms 1Neoplasm, Residual 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 11Rituximab 6Prednisone 6fludarabine 5Vincristine 5Doxorubicin 5Etoposide 4fludarabine phosphate 3Bortezomib 3Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2MLN 8237 2Electrocardiography 2Echocardiography 2Diphenhydramine 2CT-P10 2Automobiles 2Acetaminophen 2venetoclax 1varlilumab 1tositumomab I-131 1tazemetostat 1saponin QA-21V1 1romidepsin 1pomalidomide 1obinutuzumab 1molibresib 1magrolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lymphoma, B-Cell × Diphenhydramine × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡